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Acute kidney injury (AKI) is a well-known, frequent 
complication in patients after cardiac surgery, occurring in 
7% to 40%, depending on its definition (1). Subsequently, 
it is independently associated with substantial morbidity 
[such as need for renal replacement therapy, longer length 
of hospital stay and progression of chronic kidney disease 
(CKD)] and mortality (2). Even a minimal increase in post-
operative serum creatinine is associated with an increased 
mortality in cardiac surgery patients (3).
Due to the complex pathophysiology of AKI with 
multiple contributing factors, exact mechanisms are not yet 
fully understood and challenges remain concerning early 
recognition, prevention and treatment. Currently, therapy 
consist of supportive measures, while numerous studies and 
attempts on (pharmaceutical) treatment have failed to show 
beneficial effects in (cardiac surgery induced) AKI (4).
Lipid lowering therapy with 3-hydroxy-3-methylglutaryl-
CoA reductase inhibitors (statins) is a widely used therapy 
to lower cholesterol levels and prevent cardiovascular 
events. Its use among patients who undergo cardiac surgery 
is associated with a reduced incidence of perioperative 
mortality after coronary artery bypass graft surgery (5). 
Besides the lipid lowering effects of statins, established 
pleiotropic anti-inflammatory and endothelial stabilizing 
effects of statins are believed to (indirectly) contribute to 
this protective effect after cardiac surgery (6). 
As inflammatory pathways and endothelial dysfunction 
are also believed to play a major role in the development of 
AKI (7), it has been proposed that short-term use of statins 
could possibly improve renal outcome. Given this rationale, 
multiple, mostly observational, studies regarding the effect 
of statin use on renal outcome after cardiac surgery have 
been conducted and reported contradictory results. A recent 
meta-analysis by Wang et al., including 11 studies, showed 
that preoperative statin treatment reduced the incidence 
of post-operative AKI by 13% (8). However, the results of 
this meta-analysis should be interpreted with caution as the 
presence of supporting evidence of attenuation of AKI after 
cardiac surgery with preoperative statin treatment has been 
challenged (9). Prior studies examining specifically short-
term initiation of statins have also showed contradictory 
results. In a pilot randomized controlled trial (RCT) (n=100) 
short-term use of statins did not affect AKI incidence (10), 
while in a recent observational study of 17,000 patients who 
underwent cardiac surgery, a 22% lower relative risk for the 
development of AKI was observed in patients on statins in 
adjusted analyses (11). 
In this respect, Billings et al. recently tested the hypothesis 
that short-term high-dose perioperative use of statins would 
reduce AKI following cardiac surgery for both patients 
naïve to statin treatment and for patients already on chronic 
statin therapy. The primary endpoint was diagnosis of AKI 
according to the criteria form the acute kidney injury network 
(AKIN), defined by an increase of at least 0.3 mg/dL in 
serum creatinine concentration or the initiation of renal 
replacement therapy within the first 48 hours following 
cardiac surgery. Secondary endpoints included the maximum 
increase in serum creatinine concentration, the incidence 
and duration of delirium during ICU admission, the degree 
of myocardial injury, the incidence of postoperative atrial 
fibrillation, pneumonia and stroke. 
In this monocenter double-blind, placebo-controlled, 
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RCT, a total of 615 patients were enrolled. Patients naïve 
to statin treatment received 80 mg the day before surgery, 
40 mg atorvastatin on the day of surgery and 40 mg the 
day following surgery (n=102) or matching placebo (n=97). 
Patients already on statin treatment continued their 
prescribed statin dosing regimen and were randomized to 
receive either 80 mg atorvastatin on the morning of surgery 
and 40 mg the morning after surgery (n=206), or matching 
placebo (n=210). Patients scheduled for elective coronary 
artery bypass grafting (CABG), valve, and/or ascending aortic 
surgery were included. Main exclusion criteria were presence 
of acute coronary syndrome (ACS), statin intolerance, and 
liver dysfunction. Randomisation was stratified to presence 
of diabetes mellitus (DM) and the class of pre-existent 
CKD. Interim analyses by a DSMB were planned twice 
during the study at the first third and the second third of 
planned enrollment. The DSMB recommended stopping 
the group naïve to atorvastatin treatment, as patients with 
a baseline estimated GFR <60 mL/min showed increased 
AKI, and following enrollment of 615 patients the DSMB 
recommended stopping of the trial for futility. 
Overall, risk of post-operative AKI was not affected by 
short-term high-dose administration of atorvastatin. Among 
patients in the atorvastatin group 64 of 308 (20.8%) patients 
developed AKI, in the placebo group 60 of 307 (19.5%) 
patients (RR 1.06; 95% CI: 0.78–1.46; P=0.75). However, 
contrary to the hypothesis , among patients naïve to statin 
treatment AKI tended to occur more often in the treatment 
group: 22 of 102 (21.6%) patients developed AKI vs. 13 of 
97 (13.4%) patients in the placebo group (RR 1.61; 95% 
CI: 0.86–3.01; P=0.15). Also, the increase in post-operative 
serum creatinine concentration was significantly more 
distinct in the treatment group: median 0.11 mg/dL in the 
atorvastatine group vs. 0.05 mg/dL in the placebo group 
(mean difference 0.08 mg/dL; 95% CI: 0.01–0.015 mg/dL; 
P=0.007). This adverse outcome on renal function was even 
more pronounced among patients in the subgroup of pre-
existent CKD and naïve to statin treatment: AKI occurred in 
9 of 17 (52.9%) in the atorvastatin group vs. 3 of 19 (15.8%) 
in the placebo group (RR 3.35; 95% CI: 1.12–10.05; P=0.03) 
and in this subgroup a median postoperative increase in 
serum creatinine levels of 0.26 mg/dL was observed in the 
atorvastatin group vs. a median decrease of 0.06 mg/dL in 
the placebo group (mean difference 0.28 mg/dL; 95% CI: 
0.02–0.54; P=0.04). In the patients that were already on 
statin therapy, no effects of atorvastatine were observed, as 
AKI occurred in 20.4% of the active group and 22.4% of 
the placebo treated patients (RR 0.91; 95% CI: 0.63–1.32; 
P=0.63). Apart from a higher incidence and longer duration 
of delirium, and a higher incidence of atrial fibrillation in 
the atorvastatine group compared to the placebo-group, no 
statistically significant effects on the other secondary end-
points were found.
As conducted research in this field mainly included 
observational retrospective studies, the authors appreciated 
the essential need for prospective research in this field. 
In this well-conducted double-blind RCT it has been 
clearly demonstrated that there is no additional benefit for 
the initiation of high-dose short-term statin therapy. In 
contrast, short-term initiation of statin therapy in patients 
naive to the statin treatment may even be detrimental and 
enhance the development of AKI after cardiac surgery, as 
overall creatinine concentrations significantly increased 
to a greater extent in the atorvastatine group and further 
deterioration of renal function was more likely in patients 
with CKD. 
The evidence of this trial is of high quality in this double-
blind, placebo-controlled set-up, however there are some 
limitations. The authors already addressed some of these 
limitations, for example the fact that the trial was conducted 
in a single center, possibly limiting its generalizability. 
Furthermore, the definition of the primary outcome may 
pose some limitations and/or bias. First, the authors chose 
to use the AKIN criteria to define development of AKI, 
whereas for comparability the more frequently used RIFLE 
or KDIGO criteria would have possibly been a better 
option. Nevertheless, the observed increase in creatinine 
concentrations confirms the proof of principle effect on 
renal function. Second, by using AKIN criteria the authors 
committed to the corresponding post-operative window of 
48 hours, hereby not accounting for late-onset AKI. And 
last, only the creatinine criterium, not the urinary output 
criterium, to detect AKI was used. 
Further, the investigators also enrolled patients 
undergoing cardiac surgery without the use of extra 
corporeal circulation (ECC). As the use of ECC causes 
extensive activation of the innate immune system and 
exposes kidneys to ischaemia-reperfusion damage, it is 
therefore regarded as a main contributor to the development 
of post-operative AKI (12). The risk of developing AKI 
among patients without the use of ECC may therefore be 
lower. In the present cohort, surgery with the use of ECC 
was performed only in 71% of patients (n=218 atorvastatin, 
n=217 placebo), this could substantially limit the statistical 
power of the study, in particular in the smaller subgroup of 
patients naïve to statin treatment. 
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Finally, the timing of the very short treatment window 
(one day before surgery until one day after surgery) is 
remarkable and inconsistent with the multi-day treatment 
windows previously used by Prowle et al. (10) and Layton 
et al. (11). Although no other current literature describes 
adverse outcomes in patients naïve to statin treatment 
following a very short peri-operative statin dosing regimen, 
the detrimental effect as observed in this trial appears valid. 
Billings et al. have demonstrated that short-term statin 
treatment in cardiac surgery patients yields no renal benefits 
and therefore do no support initiation of statin therapy to 
prevent AKI following cardiac surgery.
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